Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221582 · ClinicalTrials.gov registry record · Phase 4
Impact of Hepatitis C Therapy and Bone Health
A Phase 4 study, sponsored by Dallas VA Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03221582: Clinical Trial Phase 4 study, sponsored by Dallas VA Medical Center.
NCT03221582 is a Phase 4 study that was terminated before completion, run by Dallas VA Medical Center. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03221582, a Phase 4 study, was terminated before completion, sponsored by Dallas VA Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.
Primary Outcome
Cardiovascular health will be assessed by serologic markers of inflammation; in addition to, positron emission tomography (PET) scanning for arterial inflammation, coronary calcification and myocardial viability.
Interventions
- DRUG EBR/GZR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 4 |
Why NCT03221582 stopped before completion
NCT03221582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which EBR/GZR is the first listed.
NCT03221582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03221582 about?
NCT03221582 is a clinical study titled "Impact of Hepatitis C Therapy and Bone Health". An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.
What is the current status of trial NCT03221582?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2017-08-28. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03221582?
The interventions under investigation include: EBR/GZR (DRUG).
Who is sponsoring clinical trial NCT03221582?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03221582's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI